iOnctura

iOnctura is a clinical-stage biopharmaceutical company focused on developing therapies for neglected and hard-to-treat cancers.

Founded in June 2017 as a spin-out from Merck Ventures, the company is headquartered in Geneva, Switzerland, with its operational parent located in Amsterdam, The Netherlands. iOnctura aims to extend patient healthspan by targeting cancers that face challenges from stroma and immune-mediated resistance. The company specializes in precision oral small molecules designed to be less toxic while effectively inhibiting tumor growth. iOnctura's pipeline includes clinical-stage candidates such as Roginolisib, the first allosteric modulator of PI3Kδ, and Cambritaxestat, the only autotaxin inhibitor in clinical development for cancer treatment. Their innovative approach emphasizes low-disruption therapies and combination therapy development, aiming to improve patient quality of life and treatment outcomes.